CardioFocus raised $20.2 million in a new round of equity and options financing, according to an SEC filing posted this week.
Money in the round came from 26 unnamed investors, with the first sale logged on Feb. 15.
The Marlborough, Mass.-based company is looking to raise another $11.9 million before closing the round, according to the SEC filing, and has not yet stated how it plans to use funds raised in the offering.
In January, CardioFocus said it launched a clinical trial of its next-generation HeartLight Excalibur balloon device designed for pulmonary vein isolation procedures.
The company said the next-gen device incorporates the balloon design from its HeartLight endoscopic ablation system alongside a new advanced feature set intended to improve speed and the magnitude of target tissue contact during procedures.
The HeartLight Excalibur balloon includes the company’s proprietary dynamic response technology intended to make the balloon responsive to technique and differing amounts of pressure applied while optimizing vein contact.